Works matching IS 25233548 AND DT 2023 AND VI 43 AND IP 3

Results: 10

μ‐opioid receptor agonist facilitates circulating tumor cell formation in bladder cancer via the MOR/AKT/Slug pathway: a comprehensive study including randomized controlled trial.

Published in:

Cancer Communications, 2023, v. 43, n. 3, p. 365, doi. 10.1002/cac2.12408

By:

Wang, Xiaoqiang;
Zhang, Song;
Jin, Di;
Luo, Jiamei;
Shi, Yumiao;
Zhang, Yiqi;
Wu, Lingling;
Song, Yanling;
Su, Diansan;
Pan, Zhiying;
Chen, Haige;
Cao, Ming;
Yang, Chaoyong;
Yu, Weifeng;
Tian, Jie

Publication type:

Article

Aerobic glycolysis promotes tumor immune evasion and tumor cell stemness through the noncanonical function of hexokinase 2.

Published in:

Cancer Communications, 2023, v. 43, n. 3, p. 387, doi. 10.1002/cac2.12404

By:

He, Haiyan;
Xiao, Liwei;
Wang, Juhong;
Guo, Dong;
Lu, Zhimin

Publication type:

Article

METTL5 stabilizes c‐Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression.

Published in:

Cancer Communications, 2023, v. 43, n. 3, p. 338, doi. 10.1002/cac2.12403

By:

Xia, Peng;
Zhang, Hao;
Lu, Haofeng;
Xu, Kequan;
Jiang, Xiang;
Jiang, Yuke;
Gongye, Xiangdong;
Chen, Zhang;
Liu, Jie;
Chen, Xi;
Ma, Weijie;
Zhang, Zhonglin;
Yuan, Yufeng

Publication type:

Article

Serologic status and safety of inactivated Covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection.

Published in:

Cancer Communications, 2023, v. 43, n. 3, p. 409, doi. 10.1002/cac2.12398

By:

Liu, Fuchen;
Feng, Xiaochen;
Du, Jin;
Ruan, Minghao;
Liu, Hui

Publication type:

Article

Activation mechanisms of clinically distinct B‐Raf V600E and V600K mutants.

Published in:

Cancer Communications, 2023, v. 43, n. 3, p. 405, doi. 10.1002/cac2.12395

By:

Zhang, Mingzhen;
Maloney, Ryan;
Liu, Yonglan;
Jang, Hyunbum;
Nussinov, Ruth

Publication type:

Article

C‐terminal variants of the P2X7 receptor are associated with prostate cancer progression and bone metastasis – evidence from clinical and pre‐clinical data.

Published in:

Cancer Communications, 2023, v. 43, n. 3, p. 400, doi. 10.1002/cac2.12391

By:

Song, Haiping;
Arredondo Carrera, Hector Manuel;
Sprules, Alexandria;
Ji, Ying;
Zhang, Tongsong;
He, Jiepei;
Lawrence, Eleanor;
Gartland, Alison;
Luo, Jian;
Wang, Ning

Publication type:

Article

Novel endogenous endoplasmic reticulum transmembrane protein SURF4 suppresses cell death by negatively regulating the STING‐STAT6 axis in myeloid leukemia.

Published in:

Cancer Communications, 2023, v. 43, n. 3, p. 395, doi. 10.1002/cac2.12390

By:

Kim, Jayoung;
Lee, Hansong;
Hong, Chae Mi;
Nam, Ji Ho;
Yeo, Hye Ju;
Cho, Woo Hyun;
Kim, Hyung‐Sik;
Hong, Changwan;
Kim, Yun Hak;
Lee, Dongjun

Publication type:

Article

Prognostic impact of circulating tumor cells in patients with soft‐tissue sarcomas: a prospective study.

Published in:

Cancer Communications, 2023, v. 43, n. 3, p. 391, doi. 10.1002/cac2.12389

By:

Blanchi, Julie;
Laroche‐Clary, Audrey;
Le Loarer, François;
Bonhomme, Benjamin;
Italiano, Antoine

Publication type:

Article

Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions.

Published in:

Cancer Communications, 2023, v. 43, n. 3, p. 297, doi. 10.1002/cac2.12387

By:

Chen, Yu‐Fei;
Xu, Ying‐ying;
Shao, Zhi‐Ming;
Yu, Ke‐Da

Publication type:

Article

Issue Information.

Published in:: Cancer Communications, 2023, v. 43, n. 3, p. 295, doi. 10.1002/cac2.12300
Publication type:: Article